SEC Company Response from Neuphoria Therapeutics (NEUP) — Nov 12, 2025
Neuphoria Therapeutics Inc.
Date: Nov. 12, 2025 · CIK: 0001191070 · Accession: 0001140361-25-041504
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-41157
Letter
Re: Neuphoria Therapeutics Inc. Preliminary Proxy Statement filed on November 12, 2025 File No. 001-41157
November 12, 2025
United States Securities and Exchange Commission Division of Corporation Finance Office of Mergers and Acquisitions 100 F Street, N.E. Washington, DC 20549
Ladies and Gentlemen:
On behalf of our client, Neuphoria Therapeutics Inc. (“Neuphoria”), and pursuant to Rule 14a-6 promulgated under the Securities Exchange Act of 1934, Neuphoria hereby files with the Securities and Exchange Commission (the “SEC”), its Preliminary Proxy Statement on Schedule 14A and the related form of proxy card (collectively, the “Neuphoria Proxy Materials”). The Neuphoria Proxy Materials have been filed with the SEC using EDGAR tag PREC14A.
The Neuphoria Proxy Materials will be furnished to Neuphoria’s stockholders in connection with the solicitation of proxies to be used at the 2025 annual meeting of stockholders of Neuphoria (the “2025 Annual Meeting”). At the 2025 Annual Meeting, stockholders will be asked to vote on, among other matters, the election of two (2) Class I directors of Neuphoria.
If the Staff of the SEC has any questions or comments concerning the accompanying Preliminary Proxy Statement or any aspects of Neuphoria’s solicitation of proxies referred to therein, please contact the undersigned at (202) 538-3557 or seandonahue@paulhastings.com.
Sincerely,
/s/ Sean M. Donahue
Show Raw Text
CORRESP 1 filename1.htm November 12, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Mergers and Acquisitions 100 F Street, N.E. Washington, DC 20549 Re: Neuphoria Therapeutics Inc. Preliminary Proxy Statement filed on November 12, 2025 File No. 001-41157 Ladies and Gentlemen: On behalf of our client, Neuphoria Therapeutics Inc. (“Neuphoria”), and pursuant to Rule 14a-6 promulgated under the Securities Exchange Act of 1934, Neuphoria hereby files with the Securities and Exchange Commission (the “SEC”), its Preliminary Proxy Statement on Schedule 14A and the related form of proxy card (collectively, the “Neuphoria Proxy Materials”). The Neuphoria Proxy Materials have been filed with the SEC using EDGAR tag PREC14A. The Neuphoria Proxy Materials will be furnished to Neuphoria’s stockholders in connection with the solicitation of proxies to be used at the 2025 annual meeting of stockholders of Neuphoria (the “2025 Annual Meeting”). At the 2025 Annual Meeting, stockholders will be asked to vote on, among other matters, the election of two (2) Class I directors of Neuphoria. If the Staff of the SEC has any questions or comments concerning the accompanying Preliminary Proxy Statement or any aspects of Neuphoria’s solicitation of proxies referred to therein, please contact the undersigned at (202) 538-3557 or seandonahue@paulhastings.com. Sincerely, /s/ Sean M. Donahue Sean M. Donahue cc: Spyridon Papapetropoulos